RNA CART-cMET (Abramson Cancer Center)

N/A

Report date: 2023/08/13 20:00:34

Base Information

Drug NameRNA CART-cMET (Abramson Cancer Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocytes stimulantsHepatocyte growth factor receptor inhibitors

TargetsHepatocyte growth factor receptor

Therapy Area/IndicationsMetastatic breast cancerTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsMetastatic breast cancerTriple Negative Breast Neoplasms

Other Information

ATC CodeN/A